Eisai Clinical Trials
Study Overview
H3B-6527
H3B-6527
NCT02834780, 2016-001915-19
Dec 2016 - Feb 2022
Hepatocellular Carcinoma (HCC)
1. Part 1, Dose Escalation Phase: Number of Participants With Dose-limiting Toxicities (DLTs) Based on National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 [Time Frame: Cycle 1 (Cycle length = 21 days)]
2. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) [Time Frame: From the first dose of study drug up to approximately 36.7 months]
-
Males and females 18 Years and older (Adult, Older Adult)
-
Completed -
Phase 1
Belgium, Canada, France, Italy, Korea, Republic of, Russian Federation, Singapore, Spain, Taiwan, United Kingdom, United States See moreData Sharing
ClinicalStudyDataRequest.com (CSDR) is a multi sponsor site through which qualified researchers who wish to access clinical trial data and associated information in order to conduct further research can submit their research proposal or enquiry.
CSDR Sharing is not available for this study.
CSDR Availability Clinical Trial Data Redacted documents may be available upon request for this study.
Document type Availability Protocol SAP Sample CRF Full CSR